Sensydia Announces American Medical Association Category III CPT® Code for Noninvasive AI Hemodynamic Assessment

Groundbreaking code will facilitate use, adoption, and pathway for reimbursement of AI-based hemodynamic assessment, including Sensydia's Cardiac Performance System (CPS™).

LOS ANGELES, Jan. 6, 2026 /PRNewswire/ -- Sensydia, a medical technology company advancing non-invasive cardiac assessment, today announced that the American Medical Association (AMA) has published a new industry-first Category III CPT® code, 1036T, for noninvasive augmentative AI hemodynamic assessment, encompassing Sensydia's Cardiac Performance System (CPS™). The new CPT code was published December 30, 2025, and will be effective July 1, 2026.

"Publication of the new AMA CPT code represents a significant milestone for Sensydia, and will help foster the adoption of our noninvasive, in-clinic hemodynamic assessment tool by establishing a pathway for reimbursement," said Anthony Arnold, CEO of Sensydia.

The new CPT code, 1036T, full descriptor is "Noninvasive hemodynamic assessment with pulmonary pressures and ejection fraction when performed, including passive acquisition of acoustic and electrical signals, augmentative algorithmic analysis, and generation of a clinical report with review, interpretation, and clinical integration by a physician or other qualified health care professional."

CPT codes are maintained and granted by the AMA CPT Editorial Panel, which is responsible for ensuring CPT codes reflect the latest medical care available to patients. These codes are widely used by government payers, including Medicare and Medicaid, and commercial insurance companies to describe healthcare services and procedures for reimbursement.

The CPS platform uses proprietary non-invasive sensors and artificial intelligence algorithms to assess in real-time key hemodynamic parameters, providing clinicians with actionable data to manage heart failure and pulmonary hypertension patients without invasive catheterization.

CPS is undergoing a multi-center pivotal study to evaluate its accuracy of hemodynamic assessment as compared to the gold-standard invasive right heart catheterization. The study's outcomes will support Sensydia's FDA submission and commercialization of CPS.

About Sensydia

Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform that provides real-time measurements of critical cardiac function. CPS is designed to deliver rapid, safe, and accurate assessments to improve outcomes for patients with heart failure and pulmonary hypertension. The company received FDA 510(k) clearance for non-invasive measurement of ejection fraction using first-generation hardware in 2018. Learn more at sensydia.com.

CPT only copyright 2025 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

SOURCE Sensydia